Intracameral more effective than subconjunctival cefuroxime

Article

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Patrick Yu-Wai-Man and colleagues at the Sunderland Eye Infirmary, UK, performed a retrospective analysis of all presumed infectious endophthalmitis cases from January 1, 2000, to December 31, 2006, and compared the rate of presumed infectious endophthalmitis in patients receiving subconjunctival cefuroxime with those receiving intracameral cefuroxime at the end of surgery.

The study, whose purpose was to compare the efficacy of intracameral cefuroxime versus subconjunctival cefuroxime in reducing the rate of endophthalmitis after cataract surgery, included 36 743 phacoemulsification cataract procedures, with a mean rate of presumed infectious endophthalmitis of 0.95 per 1000 cases. The incidence of endophthalmitis was significantly higher in the subconjunctival cefuroxime group than in the intracameral cefuroxime group.

Overall, the researchers found that intracameral cefuroxime was a safe alternative to subconjunctival cefuroxime and led to a lower rate of endophthalmitis.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.